SHP648 / Takeda - LARVOL DELTA

A Phase 1/2 Study of SHP648, an Adeno-Associated Viral Vector for Gene Transfer in Hemophilia B Subjects (clinicaltrials.gov) - P1/2; N=2; Terminated; Sponsor: Baxalta now part of Shire; No subjects have been dosed with SHP648. The decision to terminate study SHP648-101 is not due to any safety concerns.

Clinical • Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Gene Therapies • Hematological Disorders • Hemophilia • Rare Diseases

A Phase 1/2 Study of SHP648, an Adeno-Associated Viral Vector for Gene Transfer in Hemophilia B Subjects (clinicaltrials.gov) - P1/2; N=21; Suspended; Sponsor: Baxalta now part of Shire; Recruiting ➔ Suspended

Clinical • Trial suspension • Gene Therapies • Hematological Disorders • Hemophilia • Rare Diseases

A Phase 1/2 Study of SHP648, an Adeno-Associated Viral Vector for Gene Transfer in Hemophilia B Subjects (clinicaltrials.gov) - P1/2; N=21; Recruiting; Sponsor: Baxalta now part of Shire

Clinical • New P1/2 trial • Gene Therapies • Hematological Disorders • Hemophilia • Rare Diseases